Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A I / II Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetic Characteristics and Efficacy of MAX-40279 (Multi-target Tyrosine Kinase Inhibitor) Combined With KN046 (Anti-PD-L1 / CTLA-4 Bispecific Antibody) in Patients With Advanced / Metastatic Solid Tumors

Next Previous
Search
Trial Profile

A I / II Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetic Characteristics and Efficacy of MAX-40279 (Multi-target Tyrosine Kinase Inhibitor) Combined With KN046 (Anti-PD-L1 / CTLA-4 Bispecific Antibody) in Patients With Advanced / Metastatic Solid Tumors

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erfonrilimab (Primary) ; MAX-40279 (Primary)
  • Indications Gastric cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Maxinovel Pharmaceuticals

    • Most Recent Events

    • 05 Apr 2022 New trial record
    • 29 Mar 2022 According to a Alphamab Oncology media release, the company has entered into collaboration with Guangzhou MaxiNovel Pharmaceuticals to study combination of Erfonrilimab and MAX-40279. In February 2022, the Company received an IND approval from the NMPA for initiating this phase I/II clinical trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top